HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Overnight protection by inhaled salmeterol on exercise-induced asthma in children.

Abstract
The main aim of the present study was to evaluate whether inhaled salmeterol given in the evening protected against exercise-induced asthma the next morning. Twenty three children (12 males and 11 females) with a mean age of 11 yrs and with exercise-induced asthma participated in a double-blind, randomized, placebo-controlled study. The children inhaled salmeterol 25 micrograms, salmeterol 50 micrograms and placebo by Diskhaler at 10 p.m. on 3 separate days. Next morning, half of the children ran on a motor-driven treadmill for 6 min at submaximal load at 8 a.m. and the remainder at 10 a.m. Lung function was measured by maximal expiratory flow-volume loops before running, immediately after, and 3, 6, 10 and 15 min after running. The mean maximum reduction in forced expiratory volume in one second (FEV1) after treadmill run was 34% before inclusion in the study. Mean maximum fall in FEV1 was significantly greater after placebo: 30% (23-36) 95% confidence interval) than after salmeterol 25 micrograms: 19% (12-23) or salmeterol 50 micrograms: 18% (12-25). In addition to the reduced postexercise bronchoconstriction, pre-exercise lung function (FEV1) was significantly higher both after salmeterol 25 micrograms: 2.4 L.s-1 (2.1-2.7) and salmeterol 50 micrograms: 2.5 L.s-1 (2.2-2.8) than after placebo: 2.2 L.s-1 (1.9-2.5). No significant differences in pre- and postexercise lung function were found between children tested at 8 or 10 a.m., or in relation to salmeterol dosage. Thus, inhaled salmeterol 25 and 50 micrograms offered similar overnight protection against exercise-induced asthma and improved baseline lung function in the morning as compared to placebo.
AuthorsK H Carlsen, O Røksund, K Olsholt, F Njå, J Leegaard, G Bratten
JournalThe European respiratory journal (Eur Respir J) Vol. 8 Issue 11 Pg. 1852-5 (Nov 1995) ISSN: 0903-1936 [Print] England
PMID8620951 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adrenergic beta-Agonists
  • Bronchodilator Agents
  • Delayed-Action Preparations
  • Salmeterol Xinafoate
  • Albuterol
Topics
  • Administration, Inhalation
  • Adolescent
  • Adrenergic beta-Agonists (administration & dosage, therapeutic use)
  • Albuterol (administration & dosage, analogs & derivatives, therapeutic use)
  • Analysis of Variance
  • Asthma, Exercise-Induced (physiopathology, prevention & control)
  • Bronchoconstriction (drug effects)
  • Bronchodilator Agents (administration & dosage, therapeutic use)
  • Child
  • Cross-Over Studies
  • Delayed-Action Preparations
  • Double-Blind Method
  • Exercise Test
  • Female
  • Forced Expiratory Volume (drug effects)
  • Humans
  • Lung (drug effects, physiopathology)
  • Male
  • Maximal Expiratory Flow Rate (drug effects)
  • Salmeterol Xinafoate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: